Shilpa Medicare Limited (NSE: SHILPAMED) secures final approval for OERISTM, the world's first extended-release ondansetron injection, marking a significant.
Cipla Limited (NSE: CIPLA) partners with S BP Group for exclusive licensing of best-in-class HER2 bispecific ADC, aiming to enhance breast cancer treatment i.
AstraZeneca Pharma India Limited (ASTRAZEN) reports 30% revenue growth in Q1 FY2026-27, reaching INR 6,828 Mn, driven by strong portfolio and strategic partn.
Healthcare Global Enterprises Limited (HCG) reports Q1 FY27 results with 13% revenue growth, 20% Adjusted EBITDA, and improved margins.
Sakar Healthcare Limited (SAKAR) reports 38% YoY revenue growth in Q1FY27, with PAT rising 120%.
Glenmark Pharmaceuticals Limited (GLENMARK) advances its multi-country Phase 3 clinical trial for Trastuzumab rezetecan in platinum-resistant ovarian cancer.
Dr. Reddy's Laboratories Limited (DRREDDY) announces the first-to-market launch of Bosutinib Tablets 400mg in the U.S., expanding its oncology portfolio.
Natco Pharma Limited (NSE: NATCO PHARM) announces FDA approval for Eribulin Mesylate Injection, a bioequivalent to Halaven®.
Lupin Limited (LUPIN) shares positive Phase 1 data on LNP8701, a novel SOS1 inhibitor, accepted for ASCO Annual Meeting 2026.
Sakar Healthcare Limited (SAKAR) records 42% YoY revenue growth in Q4 FY26, with EBITDA rising 67%.